文献速递胸部肿瘤

Pralsetinib治疗RET融合阳性NSCLC的I/II期ARROW研究最终疗效与安全性数据

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2026-03-26

ARROW研究为I/II期开放标签研究,评估Pralsetinib 400mg每日一次治疗RET融合阳性晚期NSCLC。共281例患者入组,初治患者ORR为78%,经铂类治疗患者ORR为63%。中位OS分别为50.1个月和39.7个月,安全性可控。

要点

  • 初治RET融合阳性NSCLC患者ORR达78%,经铂治疗患者ORR为63%。
  • 初治患者中位OS为50.1个月,经铂治疗患者为39.7个月。
  • 常见≥3级治疗相关不良事件为贫血、高血压和中性粒细胞减少。

核心结论

  • Pralsetinib在初治和经治RET融合阳性NSCLC患者中均产生稳健持久的缓解,安全性可控,延长随访证实了既往结果。

研究设计与样本

  • ARROW为I/II期开放标签研究,纳入RET融合阳性NSCLC患者,接受Pralsetinib 400mg每日一次口服治疗。
  • 截至2024年5月20日数据锁定时,共281例患者开始治疗,中位治疗持续时间15.0个月。
  • 共同主要终点为客观缓解率(ORR)和安全性;关键次要终点包括缓解持续时间、无进展生存期和总生存期(OS)。

主要发现

  • 可测量疾病患者(n=259)中,初治患者ORR为78%(95%CI 69-86),经铂类化疗患者ORR为63%(95%CI 54-71)。
  • 总体中位OS为44.3个月(95%CI 30.9-53.1),初治患者为50.1个月(95%CI 28.3-未达到),经铂治疗患者为39.7个月(95%CI 27.8-53.2)。
  • 常见≥3级治疗相关不良事件包括贫血(21%)、高血压(15%)和中性粒细胞减少(13%)。
  • 发生3例治疗相关死亡(肺炎2例;间质性肺病和横纹肌溶解各1例)。
  • 安全性与此前ARROW报告一致;既往接受免疫治疗的患者中未报告超敏反应。

临床怎么用

  • Pralsetinib可作为RET融合阳性晚期NSCLC初治或经铂类化疗后的靶向治疗选择。
  • 治疗期间需监测贫血、高血压和中性粒细胞减少等常见≥3级不良事件。
  • 需警惕罕见但严重的治疗相关不良事件,包括肺炎、间质性肺病和横纹肌溶解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RET fusions appear in 1%-2% of non-small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET-altered NSCLC and RET fusion-positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion-positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion-positive NSCLCs, confirming previous findings with longer follow-up.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Besse B, Subbiah V, Curigliano G, et al. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. J Clin Oncol. 2026. PMID: 41886723. doi:10.1200/JCO-25-01489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。